BR112018007225A2 - agonistas do receptor de glucagon - Google Patents
agonistas do receptor de glucagonInfo
- Publication number
- BR112018007225A2 BR112018007225A2 BR112018007225-7A BR112018007225A BR112018007225A2 BR 112018007225 A2 BR112018007225 A2 BR 112018007225A2 BR 112018007225 A BR112018007225 A BR 112018007225A BR 112018007225 A2 BR112018007225 A2 BR 112018007225A2
- Authority
- BR
- Brazil
- Prior art keywords
- glucagon receptor
- receptor agonists
- glucagon
- native
- compounds
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
a presente invenção refere-se a compostos com uma duração prolongada de ação no receptor de glucagon em comparação com o glucagon nativo. são especificamente fornecidos agonistas do receptor de glucagon com modificações na estrutura do glucagon nativo introduzido para seletivamente tornar agonista o receptor de glucagon durante um longo período de tempo.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562246199P | 2015-10-26 | 2015-10-26 | |
US62/246,199 | 2015-10-26 | ||
PCT/US2016/056969 WO2017074715A1 (en) | 2015-10-26 | 2016-10-14 | Glucagon receptor agonists |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112018007225A2 true BR112018007225A2 (pt) | 2018-10-16 |
Family
ID=57200152
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112018007225-7A BR112018007225A2 (pt) | 2015-10-26 | 2016-10-14 | agonistas do receptor de glucagon |
BR112018006920-5A BR112018006920A2 (pt) | 2015-10-26 | 2016-10-14 | agonistas dos receptores de glucagon |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112018006920-5A BR112018006920A2 (pt) | 2015-10-26 | 2016-10-14 | agonistas dos receptores de glucagon |
Country Status (25)
Country | Link |
---|---|
US (3) | US9764004B2 (pt) |
EP (2) | EP3368060B1 (pt) |
JP (3) | JP6321299B2 (pt) |
KR (1) | KR20180053747A (pt) |
CN (2) | CN108348583B (pt) |
AR (2) | AR106318A1 (pt) |
AU (2) | AU2016344433B2 (pt) |
BR (2) | BR112018007225A2 (pt) |
CA (2) | CA3003242C (pt) |
DK (1) | DK3368060T3 (pt) |
EA (2) | EA201890676A1 (pt) |
ES (2) | ES2747908T3 (pt) |
HR (1) | HRP20201353T1 (pt) |
HU (1) | HUE050859T2 (pt) |
IL (1) | IL258092A (pt) |
LT (1) | LT3368060T (pt) |
MX (2) | MX2018005132A (pt) |
NZ (1) | NZ740644A (pt) |
PL (2) | PL3368060T3 (pt) |
PT (2) | PT3368061T (pt) |
RS (1) | RS60567B1 (pt) |
SI (1) | SI3368060T1 (pt) |
TW (1) | TWI622596B (pt) |
WO (2) | WO2017074714A1 (pt) |
ZA (2) | ZA201801756B (pt) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106536547A (zh) | 2014-06-04 | 2017-03-22 | 诺和诺德股份有限公司 | 用于医疗用途的glp‑1/胰高血糖素受体共激动剂 |
TWI622596B (zh) * | 2015-10-26 | 2018-05-01 | 美國禮來大藥廠 | 升糖素受體促效劑 |
KR20180108602A (ko) | 2015-12-23 | 2018-10-04 | 암젠 인크 | 위 억제 펩티드 수용체 (gipr)에 대한 결합 단백질을 glp-1 효능제와 조합하여 사용하여 대사 장애를 치료하거나 개선시키는 방법 |
JOP20190177A1 (ar) | 2017-01-17 | 2019-07-16 | Amgen Inc | طريقة لعلاج أو تحسين اضطرابات أيضية باستخدام مساعدات مستقبل glp-1 مقترنة بمناهضات لمستقبل ببتيد مثبط معوي (gipr) |
MX2019015544A (es) * | 2017-06-21 | 2020-07-28 | Amgen Inc | Metodo para tratar o mejorar trastornos metabolicos con proteinas de fusion de agonistas del receptor de glp-1/proteinas de union antagonistas para el receptor peptidico inhibidor gastrico (gipr). |
JP7230002B2 (ja) * | 2017-08-09 | 2023-02-28 | サノフイ | 脂肪性肝疾患および脂肪性肝炎の治療におけるglp-1/グルカゴン受容体アゴニスト |
KR20200054303A (ko) | 2017-09-22 | 2020-05-19 | 리제너론 파아마슈티컬스, 인크. | 글루카곤 유사 펩타이드 1 수용체 작용제 및 이의 용도 |
TWI744579B (zh) * | 2017-12-21 | 2021-11-01 | 美商美國禮來大藥廠 | 腸促胰島素(incretin)類似物及其用途 |
WO2019140025A1 (en) * | 2018-01-12 | 2019-07-18 | Eli Lilly And Company | Combination therapy |
WO2019140024A1 (en) | 2018-01-12 | 2019-07-18 | Eli Lilly And Company | Combination therapy |
WO2019140021A1 (en) * | 2018-01-12 | 2019-07-18 | Eli Lilly And Company | Combination therapy |
BR112020026020A2 (pt) * | 2018-07-23 | 2021-03-23 | Eli Lilly And Company | método de uso de um coagonista de gip/glp1 para diabetes |
BR112021006477A2 (pt) * | 2018-10-04 | 2021-07-13 | Hanmi Pharm. Co., Ltd. | combinação que compreende uma substância com atividade para um receptor de glucagon ou um conjugado do mesmo, kit e composição farmacêutica para prevenir ou tratar doenças |
EP3870213B1 (en) | 2018-10-26 | 2023-06-07 | Novo Nordisk A/S | Stable semaglutide compositions and uses thereof |
CN111171134B (zh) * | 2018-11-12 | 2023-08-15 | 天津药物研究院有限公司 | 胰高血糖素衍生肽及其用途 |
US20200268835A1 (en) * | 2019-02-27 | 2020-08-27 | Novo Nordisk A/S | Compounds For Use in NASH |
EP4311578A3 (en) * | 2019-06-28 | 2024-04-10 | Hanmi Pharm. Co., Ltd. | Triple agonist having activity with respect to all of glucagon, glp-1, and gip receptors for treating liver disease |
CN110684082B (zh) * | 2019-10-08 | 2021-12-10 | 江苏诺泰澳赛诺生物制药股份有限公司 | Gip和glp-1双激动多肽化合物及药学上可接受的盐与用途 |
TW202216746A (zh) | 2020-06-22 | 2022-05-01 | 印度商太陽製藥工業有限公司 | 長效型glp-1/gip雙重促效劑 |
PE20231309A1 (es) | 2020-10-17 | 2023-08-24 | Sun Pharmaceutical Ind Ltd | Agonistas duales glp-1/gip |
WO2022159395A1 (en) | 2021-01-20 | 2022-07-28 | Viking Therapeutics, Inc. | Compositions and methods for the treatment of metabolic and liver disorders |
WO2024064842A1 (en) | 2022-09-21 | 2024-03-28 | Regeneron Pharmaceuticals, Inc. | Methods of treating obesity, diabetes, and liver dysfunction |
Family Cites Families (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6004932A (en) | 1997-03-06 | 1999-12-21 | Iowa State University Research Foundation, Inc. | Use of glucagon as a metabolic conditioner for dairy cows and other ruminants |
NZ543292A (en) | 2003-06-12 | 2008-04-30 | Lilly Co Eli | GLP-1 analog fusion proteins |
CA2552526A1 (en) * | 2004-01-08 | 2005-07-21 | Theratechnologies Inc. | Glucagon-like peptide-1 analogs with long duration of action |
SG177953A1 (en) | 2007-01-05 | 2012-02-28 | Univ Indiana Res & Tech Corp | Glucagon analogs exhibiting enhanced solubility in physiological ph buffers |
NZ578948A (en) | 2007-02-15 | 2012-03-30 | Univ Indiana Res & Tech Corp | Glucagon/glp-1 receptor co-agonists |
AU2009210570B2 (en) | 2008-01-30 | 2014-11-20 | Indiana University Research And Technology Corporation | Ester-based insulin prodrugs |
AR072160A1 (es) | 2008-06-17 | 2010-08-11 | Univ Indiana Res & Tech Corp | Co-agonistas del receptor de glucagon/glp-1 |
TWI541023B (zh) | 2008-06-17 | 2016-07-11 | 印第安納大學科技研究公司 | 在生理ph緩衝液中呈現增強之溶解度及穩定性之升糖激素類似物 |
PE20100056A1 (es) | 2008-06-17 | 2010-01-26 | Univ Indiana Res & Tech Corp | Analogos de glucagon como agonistas gip |
ES2477880T3 (es) | 2008-12-15 | 2014-07-18 | Zealand Pharma A/S | Análogos del glucagón |
JP2012512903A (ja) | 2008-12-19 | 2012-06-07 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション | アミド系グルカゴンスーパーファミリーペプチドプロドラッグ |
IN2012DN00377A (pt) | 2009-06-16 | 2015-08-21 | Univ Indiana Res & Tech Corp | |
US9156901B2 (en) | 2009-07-13 | 2015-10-13 | Ditte Riber | Acylated glucagon analogues |
US8703701B2 (en) | 2009-12-18 | 2014-04-22 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
AR079344A1 (es) | 2009-12-22 | 2012-01-18 | Lilly Co Eli | Analogo peptidico de oxintomodulina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar diabetes no insulinodependiente y/u obesidad |
AR079345A1 (es) | 2009-12-22 | 2012-01-18 | Lilly Co Eli | Analogo peptidico de oxintomodulina |
US20130035285A1 (en) | 2010-03-26 | 2013-02-07 | Novo Nordisk A/S | Novel glucagon analogues |
AR080592A1 (es) | 2010-03-26 | 2012-04-18 | Lilly Co Eli | Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso |
US9040660B2 (en) * | 2010-04-20 | 2015-05-26 | Novo Nordisk A/S | Long-acting gastrin derivatives |
MX2012013005A (es) | 2010-05-13 | 2013-02-26 | Univ Indiana Res & Tech Corp | Peptidos de la superfamilia de glucagon que presentan actividad del receptor acoplado a proteinas g. |
KR101382593B1 (ko) | 2010-07-21 | 2014-04-10 | 한미사이언스 주식회사 | 신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물 |
KR20140020851A (ko) | 2010-12-22 | 2014-02-19 | 마르카디아 바이오테크, 인코퍼레이트 | Gip 및 glp-1 수용체-활성 글루카곤계 펩타이드를 이용한 대사장애 및 비만의 치료방법 |
WO2012088116A2 (en) | 2010-12-22 | 2012-06-28 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting gip receptor activity |
US20140011733A1 (en) | 2011-01-20 | 2014-01-09 | Zealand Pharma A/S | Combination of acylated glucagon analogues with insulin analogues |
JP2014510739A (ja) | 2011-03-28 | 2014-05-01 | ノヴォ ノルディスク アー/エス | 新規のグルカゴン類似体 |
EP2694095B1 (en) | 2011-04-05 | 2018-03-07 | Longevity Biotech, Inc. | Compositions comprising glucagon analogs and methods of making and using the same |
RU2014101697A (ru) | 2011-06-22 | 2015-07-27 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | Коагонисты рецепторов глюкагона/glp-1 |
PE20140724A1 (es) | 2011-06-22 | 2014-07-10 | Univ Indiana Res & Tech Corp | Coagonistas del receptor de glucagon/glp-1 |
WO2013004983A1 (en) * | 2011-07-04 | 2013-01-10 | Imperial Innovations Limited | Novel compounds and their effects on feeding behaviour |
WO2013041678A1 (en) | 2011-09-23 | 2013-03-28 | Novo Nordisk A/S | Novel glucagon analogues |
PE20142113A1 (es) * | 2011-12-23 | 2014-12-03 | Zealand Pharma As | Analogos de glucagon |
SG11201407137PA (en) | 2012-05-03 | 2014-11-27 | Zealand Pharma As | Gip-glp-1 dual agonist compounds and methods |
JP6311708B2 (ja) | 2012-06-21 | 2018-04-18 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation | Gip受容体活性を示すグルカゴンアナローグ |
HUE039267T2 (hu) | 2012-06-21 | 2018-12-28 | Univ Indiana Res & Tech Corp | GIP-receptor aktivitást mutató glukagon-analógok |
WO2014016300A1 (en) * | 2012-07-23 | 2014-01-30 | Zealand Pharma A/S | Glucagon analogues |
US9546205B2 (en) | 2012-09-17 | 2017-01-17 | Imperial Innovations Limited | Peptide analogues of glucagon and GLP1 |
UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
TWI617574B (zh) * | 2012-12-11 | 2018-03-11 | 梅迪繆思有限公司 | 用於治療肥胖之升糖素與glp-1共促效劑 |
CN104902919B (zh) | 2012-12-21 | 2018-11-20 | 赛诺菲 | Glp1/gip双重激动剂或glp1/gip/胰高血糖素三重激动剂 |
KR20160021758A (ko) | 2013-04-18 | 2016-02-26 | 노보 노르디스크 에이/에스 | 의학용으로 사용하기 위한 안정하고 연장된 glp-1/글루카곤 수용체 코-아고니스트 |
JP6230352B2 (ja) | 2013-09-19 | 2017-11-15 | ユニ・チャーム株式会社 | 動物用排泄物処理材の製造方法および製造装置 |
BR112016008115B1 (pt) | 2013-10-17 | 2024-03-12 | Boehringer Ingelheim International Gmbh | Análogos de glucagon acilados |
US9988429B2 (en) | 2013-10-17 | 2018-06-05 | Zealand Pharma A/S | Glucagon analogues |
BR112016009995B1 (pt) | 2013-11-06 | 2023-04-18 | Zealand Pharma A/S | Compostos agonistas triplos glucagon-glp-1-gip |
WO2015067715A2 (en) | 2013-11-06 | 2015-05-14 | Zealand Pharma A/S | Gip-glp-1 dual agonist compounds and methods |
US20150150643A1 (en) * | 2013-12-02 | 2015-06-04 | The Johns Hopkins University | Personalized computational modeling of atrial fibrosis to guide catheter ablation of atrial fibrillation |
TW201609799A (zh) * | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 雙重glp-1/gip受體促效劑 |
EP3080155A1 (en) * | 2013-12-13 | 2016-10-19 | Sanofi | Exendin-4 peptide analogues as dual glp-1/glucagon receptor agonists |
TW201609797A (zh) * | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 雙重glp-1/升糖素受體促效劑 |
AR098616A1 (es) * | 2013-12-18 | 2016-06-01 | Lilly Co Eli | Péptido para el tratamiento de hipoglicemia severa |
AR098614A1 (es) | 2013-12-18 | 2016-06-01 | Lilly Co Eli | Compuesto para el tratamiento de hipoglicemia severa |
AR098615A1 (es) | 2013-12-18 | 2016-06-01 | Lilly Co Eli | Péptido para el tratamiento de hipoglicemia severa |
KR20160114082A (ko) * | 2014-02-18 | 2016-10-04 | 노보 노르디스크 에이/에스 | 안정한 글루카곤 유사체 및 저혈당증의 치료를 위한 용도 |
TW201625669A (zh) * | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽-4(Exendin-4)之肽類雙重GLP-1/升糖素受體促效劑 |
US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
TWI802396B (zh) | 2014-09-16 | 2023-05-11 | 南韓商韓美藥品股份有限公司 | 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途 |
CA2972748A1 (en) | 2014-12-30 | 2016-07-07 | Hanmi Pharm. Co., Ltd. | Glucagon derivative having improved stability |
KR102418477B1 (ko) | 2014-12-30 | 2022-07-08 | 한미약품 주식회사 | 글루카곤 유도체 |
JOP20200119A1 (ar) | 2015-01-09 | 2017-06-16 | Lilly Co Eli | مركبات مساعد مشترك من gip وglp-1 |
ES2763329T3 (es) | 2015-04-16 | 2020-05-28 | Zealand Pharma As | Análogo de glucagón acilado |
WO2016198604A1 (en) | 2015-06-12 | 2016-12-15 | Sanofi | Exendin-4 derivatives as dual glp-1 /glucagon receptor agonists |
AU2016287209B2 (en) | 2015-06-30 | 2023-03-02 | Hanmi Pharm. Co., Ltd. | Glucagon derivative and a composition comprising a long acting conjugate of the same |
TW201706291A (zh) | 2015-07-10 | 2017-02-16 | 賽諾菲公司 | 作為選擇性肽雙重glp-1/升糖素受體促效劑之新毒蜥外泌肽(exendin-4)衍生物 |
TWI622596B (zh) | 2015-10-26 | 2018-05-01 | 美國禮來大藥廠 | 升糖素受體促效劑 |
-
2016
- 2016-10-07 TW TW105132649A patent/TWI622596B/zh not_active IP Right Cessation
- 2016-10-11 AR ARP160103103A patent/AR106318A1/es unknown
- 2016-10-12 AR ARP160103112A patent/AR106325A1/es unknown
- 2016-10-14 WO PCT/US2016/056959 patent/WO2017074714A1/en active Application Filing
- 2016-10-14 RS RS20200896A patent/RS60567B1/sr unknown
- 2016-10-14 PT PT167856699T patent/PT3368061T/pt unknown
- 2016-10-14 CA CA3003242A patent/CA3003242C/en active Active
- 2016-10-14 BR BR112018007225-7A patent/BR112018007225A2/pt active Search and Examination
- 2016-10-14 CA CA3000538A patent/CA3000538A1/en not_active Abandoned
- 2016-10-14 AU AU2016344433A patent/AU2016344433B2/en not_active Ceased
- 2016-10-14 PL PL16785667T patent/PL3368060T3/pl unknown
- 2016-10-14 EP EP16785667.3A patent/EP3368060B1/en active Active
- 2016-10-14 JP JP2017531687A patent/JP6321299B2/ja active Active
- 2016-10-14 MX MX2018005132A patent/MX2018005132A/es unknown
- 2016-10-14 KR KR1020187011338A patent/KR20180053747A/ko active IP Right Grant
- 2016-10-14 MX MX2018005129A patent/MX2018005129A/es active IP Right Grant
- 2016-10-14 HU HUE16785667A patent/HUE050859T2/hu unknown
- 2016-10-14 DK DK16785667.3T patent/DK3368060T3/da active
- 2016-10-14 PT PT167856673T patent/PT3368060T/pt unknown
- 2016-10-14 EA EA201890676A patent/EA201890676A1/ru unknown
- 2016-10-14 LT LTEP16785667.3T patent/LT3368060T/lt unknown
- 2016-10-14 EP EP16785669.9A patent/EP3368061B1/en active Active
- 2016-10-14 ES ES16785669T patent/ES2747908T3/es active Active
- 2016-10-14 ES ES16785667T patent/ES2809548T3/es active Active
- 2016-10-14 BR BR112018006920-5A patent/BR112018006920A2/pt not_active Application Discontinuation
- 2016-10-14 PL PL16785669T patent/PL3368061T3/pl unknown
- 2016-10-14 CN CN201680062467.6A patent/CN108348583B/zh active Active
- 2016-10-14 SI SI201630840T patent/SI3368060T1/sl unknown
- 2016-10-14 AU AU2016344434A patent/AU2016344434B2/en active Active
- 2016-10-14 US US15/293,324 patent/US9764004B2/en active Active
- 2016-10-14 US US15/293,316 patent/US9884093B2/en active Active
- 2016-10-14 WO PCT/US2016/056969 patent/WO2017074715A1/en active Application Filing
- 2016-10-14 CN CN201680062196.4A patent/CN108135981B/zh active Active
- 2016-10-14 JP JP2017531685A patent/JP6354017B2/ja active Active
- 2016-10-14 NZ NZ74064416A patent/NZ740644A/en unknown
- 2016-10-14 EA EA201890634A patent/EA038330B1/ru unknown
-
2017
- 2017-12-22 US US15/851,762 patent/US20180104312A1/en not_active Abandoned
-
2018
- 2018-03-13 IL IL258092A patent/IL258092A/en unknown
- 2018-03-14 ZA ZA201801756A patent/ZA201801756B/en unknown
- 2018-04-04 JP JP2018072110A patent/JP7211712B2/ja active Active
- 2018-04-11 ZA ZA2018/02371A patent/ZA201802371B/en unknown
-
2020
- 2020-08-27 HR HRP20201353TT patent/HRP20201353T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112018007225A2 (pt) | agonistas do receptor de glucagon | |
DK3697376T3 (da) | Sammensætning | |
EA201691911A1 (ru) | Быстродействующие композиции инсулина | |
DK3892302T3 (da) | Sammensætninger indeholdende ibrutinib | |
UA122767C2 (uk) | Ацильований аналог глюкагону | |
DK3394248T3 (da) | Dendritisk cellesammensætning | |
PH12018502274A1 (en) | Semaglutide in cardiovascular conditions | |
DK3331498T3 (da) | Nasalsammensætning | |
IL257815A (en) | Hormonal composition for stimulating follicles with increased stability | |
DK3303437T3 (da) | Polyurethan-polyisocyanurat-harpiks til fiber-kompositmaterialer med lang åben klæbetid | |
DK3397734T3 (da) | Brændstofsammensætning | |
SG11201912186SA (en) | Composition for injection | |
DK3007566T3 (da) | Anvendelse af en Bacillus-sammensætning til forøgelse af mængden af tilgængelige sukkere i dyrefoder | |
DK3393254T3 (da) | Sammensætning | |
DK3291690T3 (da) | Fodersammensætning | |
PH12018501844A1 (en) | Liraglutide in cardiovascular conditions | |
MA43304A (fr) | Benzamides substitués utiles en tant que bloqueurs de canaux sodiques | |
DK3357520T3 (da) | Viskoelastisk sammensætning | |
DK3840596T3 (da) | Sammensætning | |
BR112017016240A2 (pt) | composição | |
ES1209313Y (es) | Composicion liofilizada | |
DK3397327T3 (da) | Sprøjte med klikmekanisme | |
DK3746047T3 (da) | Injektionsbar sammensætning | |
BR112017003369A2 (pt) | composições contendo zinco com óleos essenciais | |
DK3752598T3 (da) | Allogen sammensætning |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A ANUIDADE. |
|
B08G | Application fees: restoration [chapter 8.7 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A ANUIDADE. |
|
B08G | Application fees: restoration [chapter 8.7 patent gazette] |